The key players of the chronic kidney disease-mineral and bone disorders (CKD-MBD) are calcium, phosphate, PTH, FGF23, and the vitamin D hormonal system. The progressive reduction of kidney function greatly modifies the tightly interrelated mechanisms that control these parameters. As a result, important changes occur in the bone and mineral hormonal axis, leading to changes in bone turnover with relevant consequences in clinical outcomes, such as decrease in bone mass with increased bone fragility and bone fractures and increased vascular and valvular calcification, also with great impact in the cardiovascular outcomes. So far, the knowledge of the mineral and bone disorders in CKD and the increased variety of efficacious therapies should lead to a better prevention and management of CKD-MBD.

慢性肾脏疾病-矿物质和骨骼疾病 (CKD-MBD) 的主要参与者是钙、磷酸盐、PTH、FGF23 和维生素 D 激素系统。肾功能的逐渐降低极大地改变了控制这些参数的紧密相关的机制。因此，骨和矿物质激素轴发生重要变化，导致骨转换发生变化，对临床结果产生相关后果，例如骨量减少，骨脆性增加和骨折，血管和瓣膜钙化增加，也与对心血管结局影响很大。到目前为止，对 CKD 中矿物质和骨骼疾病的了解以及有效疗法种类的增加应该可以更好地预防和管理 CKD-MBD。